North Bay Business Journal

SANTA ROSA — Osseon Therapeutics, Inc. today announced it named Ron Clough chief operating officer.

Mr. Clough’s years as an executive in the medical device industry, integrating all aspects of manufacturing, distribution, and regulatory affairs, will be a valuable asset to Osseon, according to the company.

“Osseon has a terrific opportunity to focus on the customer in the VCF marketplace. We plan to leverage the depth of expertise within our employees to the benefit of patients, physicians, and distributors in our arena,” Mr.  Clough said.

Mr. Clough has experience with several companies that develop and market medical devices for treatment of spinal disease and deformities. Most recently, he served as vice president of operations at Theken Spine and was a key executive in the acquisition and integration of Theken Spine into Integra LifeSciences, an international medical device company.

Integra LifeSciences acquired Theken in July 2008 for $200 million dollars in a two-year earnout . 

“Osseon is very excited that Mr. Clough has joined the management team,” said John Stalcup, Ph.D., president. ”He brings unparalleled experience and expertise in the spinal device market.”

Osseon (707-636-5940, osseon.com) focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease. Its first-generation products have received both FDA clearance and the CE Mark for product distribution in the United States and European Union.